stars 1 stars 2 stars 3

Amakem is biopharmaceutical company focusing on kinase inhibitors for treatments for Bowel (IBD, Crohn, Colitis), Eye (DR, DME, AMD) and Lung (PAH, IPF, COPD and asthma) diseases. Amakem's product pipeline is based on its unique 'Localized Drug Action' platform which generates novel kinase (Rock and LIM) inhibitors.

Website https://www.amakem.com
Revenue $6.2 million
Employees 1 (0 on RocketReach)
Founded 2010
Address Bioville Agoralaan Bldg a Bis, Diepenbeek, Flanders 3590, BE
Phone +32 11 28 69 82
Technologies
Industry Biotechnology, Pharmaceutical Manufacturing, Drug Stores & Pharmacies, Drug Discovery, Research Services, Retail, Science and Engineering, Pharmaceuticals, Kinase Inhibitors, Medical, Medicinal Chemistry, Health Care, Opthalmology, Therapeutics, Lung diseases, Inflammatory bowel disease
Keywords Kinase Inhibitors, Biopharmaceutical, Drug Development, Bowel Disease Treatment, Crohn's Disease Treatment, Eye Disease Treatment, Diabetic Retinopathy Treatment, Lung Disease Treatment, Asthma Treatment, Targeted Therapy, Precision Medicine, Pharmaceutical Research
Competitors Novartis, Pfizer, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Merck & Co., Inc., GSK, Johnson & Johnson, Sanofi, Roche +50 more (view full list)
SIC SIC Code 283 Companies, SIC Code 28 Companies
NAICS NAICS Code 325 Companies, NAICS Code 32541 Companies, NAICS Code 3254 Companies, NAICS Code 32 Companies

Amakem NV Questions

The Amakem NV annual revenue was $6.2 million in 2026.

Amakem NV is based in Diepenbeek, Flanders.

The NAICS codes for Amakem NV are [325, 32541, 3254, 32].

The SIC codes for Amakem NV are [283, 28].

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users